The effects of calcitonin on acute bone loss after pertrochanteric fractures. A prospective, randomised trial

Journal of Bone and Joint Surgery - Series B

Volumn 86, Issue 3, 2004, Pages 350-358

  Karachalios, T ^a   Lyritis, G P ^b   Kaloudis, J ^b   Roidis, N ^a   Katsiri, M ^b  

^a Faculty of Health and Care   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ALKALINE PHOSPHATASE BONE ISOENZYME; ANTIBIOTIC AGENT; CARBOXY TERMINAL TELOPEPTIDE; HYDROXYPROLINE; LOW MOLECULAR WEIGHT HEPARIN; OSTEOCALCIN; PLACEBO; SALCATONIN;

ACUTE DISEASE; AGED; ARTICLE; BONE DENSITY; BONE MINERAL; CLINICAL ARTICLE; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; FEMALE; FEMUR PERTROCHANTERIC FRACTURE; FRAGILITY FRACTURE; GERIATRIC PATIENT; HIP FRACTURE; HUMAN; HYDROXYPROLINE URINE LEVEL; INCIDENCE; OSTEOLYSIS; OSTEOPOROSIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ACUTE DISEASE; ADMINISTRATION, INTRANASAL; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE DENSITY; CALCITONIN; COLLAGEN; COLLAGEN TYPE I; FEMALE; HIP FRACTURES; HUMANS; HYDROXYPROLINE; OSTEOCALCIN; OSTEOLYSIS; PEPTIDES; PROSPECTIVE STUDIES; RECURRENCE;

EID: 2342433837     PISSN: 0301620X     EISSN: None     Source Type: Journal    
DOI: 10.1302/0301-620X.86B3.14300     Document Type: Article

References (52)

1. Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Osteoporosis Int 1994;4:368-81.
2. Johnell O, Gullberg B, Allander E, Kanis JA. The apparent incidence of hip fracture in Europe: a study of national registers sources. Osteoporosis Int 1992;2: 298-302.
3. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. New Engl J Med 1995;332:767-73.
4. Egol KA, Koval KJ, Zuckerman JD. Functional recovery following hip fracture in the elderly. J Orthop Trauma 1997:11:594-9.
5. Lips P, van Ginkel FC, Netelenbos JC, Wiersinga A, ven der Vijgh WJ. Lower mobility and markers of bone resorption in the elderly. Bone Miner 1990;9:49-57.
6. Carter DR. Mechanical loading histories and cortical bone remodelling. Calcif Tissue Int 1984;36Suppl:19-24.
7. Dretakis KE, Dretakis EK, Papakitsou EF, Psarakis S, Steriopoulous K. Possible predisposing factors for the second hip fracture. Calcif Tissue Int 1998;62:366-9.
8. Schroder HM, Petersen KK, Erlandsen M. Occurrence and incidence of the second hip fracture. Clin Orthop 1993;289:166-9.
9. Dretakis EK, Kritsikis N, Economou K, Christodoulou N. Bilateral noncontemporary fractures of the proximal femur. Acta Orthop Scand 1981:52:227-9.
10. Finsen V, Benum P. The second hip fracture: an epidemiologic study. Acta Orthop Scand 1986;57:431-3.
11. Boston DA. Bilateral fractures of the femoral neck. Injury 1982;14:207-10.
12. Reginster JY, Denis D, Albert A, et al. One-year controlled randomised trial of prevention of early postmenopausal bone loss by intranasal calcitonin. Lancet 1987;26:2: 1481-3.
13. Overgaard K, Hansen MA, Nielsen V-AH, Riis BJ, Cristiansen C. Discontinuous calcitonin treatment of established osteoporosis: effects of withdrawal of treatment. Am J Med 1990;89:1-6.
14. Peyron R, Serrurier D, Edouard C, et al. Treatment of high remodelling vertebral osteoporosis with human calcitonin: a two-year double blind placebo-controlled trial in 93 patients. Osteoporosis 1990:1430-3.
15. Overgaard K, Hansen MA, Jensen SB, Christiansen C. Effect of calcitonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose dependent study. BMJ 1992;305:556-61.
16. Chesnut C, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. Am J Med 2000;109:267-76.
17. Kanis JA, Johnell O, Gullberg B, et al. Evidence for the efficacy of bone active drugs in the prevention of hip fracture. BMJ 1992;305:1124-8.
18. Tsakalakos N, Magiasis B, Tsekoura M, Lyritis G. The effect of short-term calcitonin administration on biochemical bone markers in patients with acute immobilization following hip fracture. Osteoporosis Int 1993;3:337-40.
19. Van der Wiel HE, Lips P, Nauta J, et al. Intranasal calcitonin suppresses increased bone resorption during short-term immobilization: a double-blind study of the effects of intranasal calcitonin on biochemical parameters of bone turnover. J Bone Miner Res 1993;8:1459-65.
20. Rencken ML, Murano R, Drinkwater BL, Chesnut CH 3rd. In vitro compatability of dual energy x-ray absorptiometry (DEXA) bone densitometers. Calc Tissue Int 1991; 48:245-8.
21. Thomas T, Skerry TM, Vico L, et al. Ineffectiveness of calcitonin on a local-disuse osteoporosis in the sheep: a histomorphometric study. Calcif Tissue Int 1995;57: 224-8.
22. Bloomfield SA. Changes in musculoskeletal structure and function with prolonged bed rest. Med Sci Sports Exerc 1997;29:197-206.
23. Minaire P, Meunier P, Edouard C, et al. Quantitative histological data on disuse osteoporosis. Calcif Tissue Res 1974;17:57-73.
24. Krolner B, Toft B. Vertebral bone loss: an unheeded side effect of bed rest. Clin Sci (Lond) 1983;64:537-40.
25. Bischoff H, Stahelin HB, Vogt P, et al. Immobility as a major cause of bone remodelling in residents of a long-stay geriatric ward. Calcif Tissue Int 1999;64:485-9.
26. Fiore CE, Pennisi P, Ciffo F, et al. Immobilization-dependent bone collagen breakdown appears to increase with time: evidence for a lack of new bone equilibrium in response to reduced load during prolonged bed rest. Horm Metab Res 1999; 31:31-6.
27. Mazess RB, Whedon GD. Immobilization and bone. Calcif Tissue Int 1983;35:265-7.
28. Schneider VS, McDonald J. Skeletal calcium homeostasis and countermeasures to prevent disuse osteoporosis. Calcif Tissue Int 1984; 36Suppl:151-4.
29. Raisz LG, Smith JA. Osteoporosis. In: Martin TJ, Raisz LG, eds. Clinical endocrinology and calcium metabolism. Marcel Dekker, London, 1987:211-4.
30. Garnero P, Delmas PD. New developments in biochemical markers for osteoporosis. Calcif Tissue Int 1996;59 (Suppl 1):2-9.
31. Garnero P, Delmas PD. Bone markers, Balliere's Clinical Rheumatology. 1997;11: 517-37.
32. Thompson SP, White DA, Hosking DJ, Wilton TJ, Pawley E. Changes in osteocalcin after femoral neck fracture. Ann Clin Biochem 1989;26:487-91.
33. Delmi M, Ropin HA, Bengoa JM, et al. Dietary supplementation in dietary patients with fractured neck of femur. Lancet 1990;335:1013-6.
34. Akesson K, Vergnaud P, Gineyts E, Delmas PD, Obrant KJ. Impairment of bone turnover in elderly women with hip fractures. Calcif Tissue Int 1993;53:162-9.
35. Garnero P, Housher E, Chapuy MC, et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS prospective study. J Bone Miner Res 1996;11: 1531-8.
36. Reginster JY, Jupsin I, Deroisy R, et al. Prevention of postmenopausal bone loss by rectal calcitonin. Calcif Tissue Int 1995;56:539-42.
37. Kollerup G, Hermann AP, Brixen K, et al. Effects of salmon calcitonin suppositories on bone mass and turnover in established osteoporosis. Calcif Tissue Int 1994;54: 12-5.
38. Delmas PD, Garnero P. Biological markers of bone turnover in osteoporosis. In: Stevenson JC and Lindsay R, eds. Osteoporosis. Chapman & Hall, London, 1998:90-105.
39. Delmas PD. Biochemical markers of bone turnover for the clinical investigation of osteoporosis. Osteoporosis Int 1993;3(Suppl 4):81-6.
40. Eyre DR. Bone biomarkers as tools in osteoporosis management. Spine 1997;15: 22(Suppl):17-24.
41. Garnero P, Delmas PD. Biochemical markers of bone turnover: clinical usefulness in osteoporosis. Ann Biol Clin (Paris) 1999;57:137-48.
42. De la Piedra C, Traba ML, Dominguez Cabrera C, Sosa Henriquez M. New biochemical markers of bone resorption in the study of postmenopausal osteoporosis. Clin Chim Acta 1997;265:225-34.
43. Eyre DR. Biomechanical markers of bone turnover. Spine 1997;22(Suppl):114-8.
44. Bonde M, Qvist P, Fledelius C, Rils BJ, Christiansen C. Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps): follow up on hormone replacement therapy and osteoporosis risk assessment. J Clin Endocrinol Metab 1995;80:864-8.
45. Guerrero R, Diaz Martin MA, Diaz Diego EM, et al. New biochemical markers of bone resorption derived from collagen breakdown in the study of postmenopausal osteoporosis. Osteoporos Int 1996;6: 297-302.
46. Overgaard K, Christiansen C. A new biochemical marker of bone resorption for follow-up on treatment with nasal salmon calitonin. Calcif Tissue Int 1996;59:12-6.
47. Dirschl OR, Henderson RC, Oakley WC. Accelerated bone mineral loss following a hip fracture: a prospective longitudinal study. Bone 1997;21:79-82.
48. Nakumara N, Kyou T, Takaoka K, Ohzono K, Ono K. Bone mineral density in the proximal femur and hip fracture type in the elderly. J Bone Miner Res 1992;7:755-9.
49. Tanizawa T, Imura K, Ishii Y, et al. Treatment with active vitamin D metabolites and concurrent treatments in the prevention of hip fractures: a retrospective study. Osteoporos Int 1999;9:163-70.
50. Shen Y, Li M, Wronski TKJ. Calcitonin provides complete protection against cancellous bone loss in the femoral neck of ovariectomized rats. Calcif Tissue Int 1997; 60:457-61.
51. Ellerington MC, Hillard TC, Whitcroft SI, et al. Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis. Calcif Tissue Int 1996; 59:6-11.
52. Lyritis GP, Magiasis B, Tsakalakos N. Prevention of bone loss in early nonsurgical and nonosteoporotic high turnover patients with salmon calcitonin: the role of biochemical bone markers in monitoring high turnover patients under calcitonin therapy. Calcif Tissue Int 1995;56:38-41.